Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/s41571-019-0267-4.pdf
Reference174 articles.
1. Berdasco, M. & Esteller, M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 19, 698–711 (2010).
2. Morel, D., Almouzni, G., Soria, J.-C. & Postel-Vinay, S. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Ann. Oncol. 28, 254–269 (2017).
3. DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386–2398 (2018).
4. Italiano, A. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19, 649–659 (2018).
5. Stathis, A. et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 6, 492–500 (2016).
Cited by 319 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data;Clinical Nutrition ESPEN;2024-10
2. Unlocking the potential of icaritin derivatives: Synthesis, characterization, and antiproliferative activity against MCF-7 breast cancer cells;Journal of Molecular Structure;2024-10
3. Research hotspots and trends of epigenetic therapy in oncology: a bibliometric analysis from 2004 to 2023;Frontiers in Pharmacology;2024-09-12
4. Exploring the impact of circRNAs on cancer glycolysis: Insights into tumor progression and therapeutic strategies;Non-coding RNA Research;2024-09
5. Deciphering Depression: Epigenetic Mechanisms and Treatment Strategies;Biology;2024-08-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3